Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. (PATRON-Study).

Trial Profile

A pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. (PATRON-Study).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2012

At a glance

  • Drugs Basiliximab (Primary) ; Daclizumab (Primary) ; Mycophenolate mofetil (Primary) ; Sirolimus (Primary) ; Corticosteroids; Mycophenolate mofetil; Prednisolone
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Acronyms PATRON
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 01 Sep 2012 Status changed from recruiting to completed., according to European Clinical Trials database.
    • 01 Sep 2012 Additional trial source identified from European clinical trials database and integrated (EudraCT2007-003561-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top